fda warning peptides bpc-157 october 2025 are nearly everywhere in fitness marketing, but the gap between the influencer hype and the clinical evidence is massive. We just did a forensic audit of the entire market. We covered 83% of peptide-aware Americans want
83% of peptide aware Americans want the FDA to make peptides more accessible Globe Miami Times The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet Thursday and Friday to review some of the controversial, popular peptide injections and discuss whether compounding pharmacies should be able to dispense A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a Warning Letter to Platinum Biologics LLC for marketing umbilicalcordderived products including exosome products (NanoEx & Nano Xsomes) without approval. The hype around a new class of injectable drugs is in overdrive, but they have yet to be properly tested. Read the full story from Kishor Napier Raman at the link in bio., Photo: Oscar Colman BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health &
Pay in 4 interest-free payments of $6.90 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

